Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables rises 171.8% from a year ago
Net receivables stood at $106K at the end of Q2 FY2026, up 171.8% from a year earlier and down 91.4% from the prior quarter. Over 3 fiscal years it compounded at -73.7% a year.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +171.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 102K USD
- Year-over-year change
- -87.4%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 102K | -87.4% |
| FY2024 | 2024-12-31 | 807K | +68.8% |
| FY2023 | 2023-12-31 | 478K | -91.5% |
| FY2022 | 2022-12-31 | 5.64M | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's Jun 2026 net receivables of $106K is the 8th highest of the 10 companies compared; the peer median is $261K.
- Its year-over-year change of +171.8% is the highest of 10, against a peer median of -84.7%.
- Net receivables amounts to 0.0% of total assets for DNTH, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $25.75M | +44.0% | +187.9% | 7.8% | |
| Mar 2026 | $5.76M | +92.9% | +182.0% | 1.4% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $3.86M | -50.9% | +60.9% | 0.7% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $600K | -42.0% | +13.5% | 0.6% |
| Mar 2026 | $261K | -85.2% | -51.6% | 0.1% | |
| Dec 2025 | $161K | -84.7% | -11.5% | 0.3% | |
| Sep 2026 | $138K | -93.0% | +64.6% | 0.0% | |
| Jun 2026 | $106K | +171.8% | -73.7% | 0.0% | |
| Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding DNTH) | $261K | -84.7% | +60.9% | 0.3% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 131.65M | 15.37M | 132.33M | 22.79M | 51.09M |
| Short-term Investments | 45.28M | 60.13M | 41.39M | 252.45M | 353.21M |
| Net Receivables | 0 | 5.64M | 478K | 807K | 102K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 3.77M | 53K | 504K | 355K | 5.04M |
| Total Current Assets | 180.69M | 82.03M | 177.45M | 280.9M | 409.44M |
| Property, Plant & Equipment (Net) | 7.46M | 956K | 800K | 1.75M | 1.63M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.78M | 0 | 0 | 81.73M | 110.14M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 121K | 1.15M | 9.63M | 9.72M |
| Total Non-current Assets | 9.24M | 1.08M | 1.95M | 93.1M | 121.48M |
| Total Assets | 189.93M | 83.11M | 179.41M | 374.01M | 530.92M |
| Account Payables | 3.04M | 1.17M | 2.61M | 4.58M | 9.73M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 100K | 100K | 479K | 1.19M |
| Other Current Liabilities | 4.48M | 2.08M | 5.36M | 5.15M | 9.52M |
| Total Current Liabilities | 10.86M | 8.23M | 9.63M | 18.45M | 30.73M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 791K | 736K | 1.91M | 5.77M |
| Other Non-current Liabilities | 6.4M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 6.4M | 1.23M | 904K | 3.08M | 6.79M |
| Total Liabilities | 17.26M | 9.45M | 10.54M | 21.53M | 37.52M |
| Common Stock | 59K | 0 | 15K | 31K | 43K |
| Retained Earnings | (325.57M) | (45.87M) | (89.42M) | (174.39M) | (336.73M) |
| Accumulated OCI | (30K) | (161K) | 47K | 106K | 489K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 172.67M | 73.66M | 168.87M | 352.48M | 493.4M |
| Total Debt | 0 | 788K | 585K | 1.49M | 1.39M |
| Net Debt | (131.65M) | (14.58M) | (131.74M) | (21.3M) | (49.7M) |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.